In the foreground, TMTV, reflecting the whole tumor burden (TB), has value in predicting whether patients treated with anti-PD1 will respond to therapy, and whether they will die of melanoma [26,27] or NSCLC [19,28]. The gene discussed is PDCD1; the disease is neoplasm.